NEUP vs PATH · rev $15.0M vs P/E 19, rev $1.61B
Neuphoria Therapeutics Inc (NEUP) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Neuphoria Therapeutics Inc (NEUP) is a biotechnology company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported NEUP revenue for 2025-03-31 was $15.0M. Net income was $11.3M. NEUP currently screens at market cap $23.6M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
NEUP currently screens at market cap $23.6M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the NEUP and PATH stock pages for the full models.
Not investment advice.